| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
| Targets |
(R)-Leucic acid does not have a specific well-defined pharmacological target, as it is primarily used as a research reagent and metabolite. As an amino acid metabolite, it may interact with enzymes involved in amino acid metabolism, such as branched-chain amino acid aminotransferase or α-ketoacid dehydrogenase. Its role as a metabolite in maple syrup urine disease makes it relevant for studying metabolic disorders.
|
|---|---|
| ln Vitro |
(R)-Leucic acid exhibits in vitro activity as an amino acid metabolite. It is used as a research reagent to study amino acid metabolism and metabolic disorders. Its activity is assessed in biochemical assays measuring enzyme activity or metabolic flux. These in vitro activities confirm its utility as a research tool in metabolism research.
|
| ln Vivo |
(R)-Leucic acid is not typically used as a therapeutic agent in vivo. However, as a metabolite, it may be involved in various physiological processes. In patients with short bowel syndrome and maple syrup urine disease, its levels are altered. In toxicological studies, it may be evaluated for its effects on metabolism and excretion. Its metabolic fate in vivo involves conversion to other metabolites.
|
| Enzyme Assay |
(R)-Leucic acid does not have specific enzyme/receptor binding assays associated with it, as it is not a typical drug target compound. However, its role as a metabolite can be studied using enzyme assays for branched-chain amino acid metabolism. Its levels in biological samples can be measured using LC-MS or other analytical techniques.
|
| Cell Assay |
(R)-Leucic acid is not typically used in cellular assays as a pharmacological agent. However, its effects on metabolism can be studied in cell culture models. Cytotoxicity assays can be performed to assess the compound's effects on cell viability. Metabolic flux analysis can be used to study its effects on cellular metabolism. These assays are primarily used in metabolomics and biochemical research.
|
| Animal Protocol |
In vivo animal experiments with (R)-Leucic acid are primarily conducted for metabolic and toxicological studies. Rodent models of maple syrup urine disease or other metabolic disorders may be used. The compound's levels in plasma, urine, and tissues are measured. These studies help define the compound's role in metabolic disorders.
|
| ADME/Pharmacokinetics |
(R)-Leucic acid is a small, polar molecule with a molecular weight of 132.16. It is soluble in water and organic solvents. Its pharmacokinetic profile is typical for small polar molecules. The compound is typically stored at -20°C.
|
| Toxicity/Toxicokinetics |
(R)-Leucic acid is considered to have low toxicity based on its use as a research compound and its occurrence as a natural metabolite. However, comprehensive toxicological evaluations have not been extensively published. The compound is intended for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
(R)-2-hydroxy-4-methylvaleric acid is the (R)-enantiomer of 2-hydroxy-4-methylvaleric acid. It is found in patients with short bowel syndrome (a congenital metabolic disorder) and maple syrup urine disease (MSUD). It is a (2R)-2-hydroxy monocarboxylic acid and a 2-hydroxy-4-methylvaleric acid. It is the conjugate acid of (R)-2-hydroxy-4-methylvaleric acid ester. It is the enantiomer of (S)-2-hydroxy-4-methylvaleric acid. (R)-2-hydroxy-4-methylvaleric acid has been reported to exist in Homo sapiens, Euglena, and Caenorhabditis elegans, and relevant data are available.
(R)-Leucic acid ((2R)-2-hydroxy-4-methylpentanoic acid) is an amino acid metabolite. It is also known as D-leucic acid. The compound is a derivative of leucine. It is found in patients with short bowel syndrome and maple syrup urine disease. It is available in high purity (≥98%) for research applications. Its role as a metabolite makes it a valuable tool for studying amino acid metabolism and metabolic disorders. |
| Molecular Formula |
C₆H₁₂O₃
|
|---|---|
| Molecular Weight |
132.16
|
| Exact Mass |
132.079
|
| CAS # |
20312-37-2
|
| PubChem CID |
439960
|
| Appearance |
White to off-white solid powder
|
| Density |
1.763g/cm3
|
| Boiling Point |
673.6ºC at 760mmHg
|
| Flash Point |
375.2ºC
|
| Vapour Pressure |
0.00324mmHg at 25°C
|
| Index of Refraction |
1.457
|
| LogP |
0.478
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
98.5
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)C[C@H](C(=O)O)O
|
| InChi Key |
LVRFTAZAXQPQHI-RXMQYKEDSA-N
|
| InChi Code |
InChI=1S/C6H12O3/c1-4(2)3-5(7)6(8)9/h4-5,7H,3H2,1-2H3,(H,8,9)/t5-/m1/s1
|
| Chemical Name |
(2R)-2-hydroxy-4-methylpentanoic acid
|
| Synonyms |
(R)Leucic acid; (R) Leucic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~756.66 mM)
H2O : ~100 mg/mL (~756.66 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.92 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 33.33 mg/mL (252.19 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.5666 mL | 37.8329 mL | 75.6659 mL | |
| 5 mM | 1.5133 mL | 7.5666 mL | 15.1332 mL | |
| 10 mM | 0.7567 mL | 3.7833 mL | 7.5666 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
